{
  "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
  "docSlug": "810e8355c3b124b062a449d6b3848ba9",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 49,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes detailed source citations in the footer; uses a color-coded legend for different drug treatments.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/11",
  "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
  "deckJsonHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41.json",
  "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Comparison of Disease Control and median PFS for STS and Colorectal Cancer",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ddc92522-0bfe-4f50-a609-dac855e929e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.28,
        "x": 0.7,
        "y": 0.15
      },
      "kind": "list",
      "text": "IMX-110 category leading progression free survival (PFS) in heavily pretreated patients with zero drug-related SAEs; IMX-110 100% Disease Control at 2 months; IMX-110 treated STS patients had 3-13 median prior lines of therapies; IMX-110 + PD-1 treated r/r colorectal cancer showed 75% tumor shrinkage and mPFS not reached (NR) at 2 months in patients had 8 median prior lines of therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33ac14d3-774e-44bd-abdc-228eb4aae557",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Note: mPFS is Median Progression Free Survival. Adapted from various clinical trial sources listed in the footer.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fa90d27-f0ea-441e-a70a-cd996f2e5aaa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "IMX-110 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in Soft Tissue Sarcoma (STS), and Encouraging Efficacy in Colorectal Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f830c51-9b21-467c-abe3-6bf6d8076ca9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "a5c93686-f1b0-4794-af18-e7f7b7eee64a",
      "evidence": "Direct comparison of clinical trial metrics between IMX-110 and standard-of-care drugs.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 21,
      "from": 8,
      "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
      "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
      "position": 0,
      "objective": "Highlighting the need for improved therapies",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}